StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
84
This year
7
Publishing Date
2024 - 02 - 27
2
2023 - 12 - 11
2
2023 - 12 - 06
2
2023 - 10 - 24
1
2023 - 08 - 31
1
2023 - 08 - 30
1
2023 - 08 - 16
1
2023 - 07 - 26
1
2023 - 07 - 03
1
2023 - 05 - 17
1
2023 - 05 - 11
2
2023 - 05 - 04
2
2023 - 05 - 03
4
2023 - 05 - 02
1
2023 - 04 - 28
1
2023 - 04 - 20
3
2023 - 04 - 17
1
2023 - 04 - 04
1
2023 - 03 - 31
1
2023 - 03 - 29
1
2023 - 03 - 28
2
2023 - 03 - 21
1
2023 - 03 - 08
1
2023 - 03 - 06
1
2023 - 02 - 28
1
2023 - 02 - 27
1
2023 - 02 - 17
1
2023 - 02 - 15
1
2023 - 01 - 27
1
2023 - 01 - 26
1
2023 - 01 - 11
1
2023 - 01 - 06
1
2023 - 01 - 05
1
2022 - 12 - 15
1
2022 - 12 - 09
1
2022 - 12 - 05
1
2022 - 11 - 28
1
2022 - 11 - 15
1
2022 - 11 - 14
1
2022 - 11 - 08
1
2022 - 11 - 07
1
2022 - 10 - 31
1
2022 - 10 - 17
1
2022 - 10 - 10
2
2022 - 09 - 08
1
2022 - 09 - 06
1
2022 - 09 - 05
1
2022 - 08 - 30
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 11
1
2022 - 08 - 10
1
2022 - 08 - 08
2
2022 - 07 - 28
1
2022 - 02 - 24
1
2022 - 02 - 01
1
2022 - 01 - 11
1
2021 - 12 - 21
1
2021 - 12 - 14
1
2021 - 11 - 04
1
Sector
Communications
1
Consumer durables
1
Consumer non-durables
1
Distribution services
1
Health technology
84
Industrial services
1
Manufacturing
4
N/a
5
Professional, scientific, and technical services
1
Retail trade
1
Technology services
2
Tags
Acquisition
1
Agonist
2
America
2
Antibiotics
1
Antibody
1
Application
1
Approval
1
Approved
1
Australia
2
Bioforest
1
Biotech
2
Biotech-bay
1
Cancer
5
Cell
2
China
4
Chinese
8
Collaboration
2
Designation
2
Diagnostics
2
Disease
6
Drug
2
Earnings
2
Europe
3
Expected
2
Financial results
2
Global
20
Growing
3
Growth
10
Ibi311
3
Ibi351
3
Ibi362
3
Lung
4
Macular
2
Market
29
Medical
3
Meeting
3
N/a
79
Obesity
4
Pharma
3
Phase 1
4
Phase 2
2
Plus
3
Protein
2
Reach
8
Report
15
Research
5
Results
10
Sanofi
2
Sciences
2
Spac
5
Study
16
Therapeutics
8
Therapy
2
Thyroid
3
Treatment
9
Trial
3
Trials
2
Tumors
2
Update
2
Vaccine
2
Entities
Abbott laboratories
4
Abbvie inc.
9
Accenture plc
1
Adagene inc - adr
1
Adma biologics inc
1
Aecom
1
Alibaba group holding ltd
1
Alpine immune sciences, inc.
1
Amgen inc.
5
Amicus therapeutics, inc.
1
Astellas pharma inc
2
Astrazeneca plc
7
Bausch health companies inc.
1
Baxter international inc.
2
Becton, dickinson and company
2
Biogen inc.
2
Biontech se
2
Brainstorm cell therapeutics inc.
1
Bridgford foods corporation
1
Bristol-myers squibb company
1
Conagra brands, inc.
1
Csl ltd
3
Danaher corporation
2
Denali therapeutics inc.
1
Eli lilly and company
31
Glaxosmithkline plc
11
Grifols sa
1
Hormel foods corporation
1
Icon plc
1
Incyte corporation
23
Johnson & johnson
8
Kenvue inc.
2
Koninklijke philips nv
1
Lonza group ag
1
Mckesson corporation
1
Mobiv acquisition corp
1
Myriad genetics, inc.
1
Novartis ag
16
Novo nordisk a/s
3
Obseva sa
1
Omnicell, inc.
1
Opko health, inc.
1
Orange
1
Pfizer, inc.
2
Provention bio, inc.
6
Rcf acquisition corp.
2
Regeneron pharmaceuticals, inc.
1
Resmed inc.
1
Sangamo therapeutics, inc.
1
Sanofi
84
Sleep number corporation
1
Smith & nephew plc
1
Stryker corporation
1
Takeda pharmaceutical company limited
3
Teva pharmaceutical industries ltd
5
Thermo fisher scientific inc
2
Tyson foods, inc.
1
Ucb s.a.
1
Verastem, inc.
1
Viatris inc.
3
Symbols
AAPL
31
ABB
43
ABBV
32
ABLZF
37
ABT
49
ACM
16
ACN
28
AMGN
23
ARVL
59
AVGO
21
AZN
19
AZNCF
16
BAX
25
BNPQF
18
BNPQY
18
CLVLF
23
CLVLY
23
CMI
16
CNS
19
DELL
23
DNZOF
17
DNZOY
17
ERIC
26
FNCTF
141
GILD
17
GLAXF
25
GOOG
32
GOOGL
32
GSK
26
HCM
19
HON
51
INCY
73
JCI
19
JNJ
66
LLY
112
LMNR
27
LTUM
18
LYV
18
MDT
22
MESO
26
MMM
19
MS
92
MSFT
20
NVS
47
NVSEF
44
PCRFF
19
PCRFY
19
PD
18
PHG
18
PPRUF
21
PPRUY
21
RYLPF
24
SAP
34
SAPGF
31
SNEJF
18
SNY
87
SNYNF
84
SYK
20
TEVJF
17
TMO
38
Exchanges
Nasdaq
84
Nyse
56
Crawled Date
2024 - 02 - 27
2
2023 - 12 - 11
2
2023 - 12 - 06
2
2023 - 10 - 27
1
2023 - 10 - 24
1
2023 - 08 - 31
1
2023 - 08 - 30
1
2023 - 08 - 16
1
2023 - 07 - 26
1
2023 - 07 - 03
1
2023 - 05 - 17
1
2023 - 05 - 11
2
2023 - 05 - 04
2
2023 - 05 - 03
4
2023 - 05 - 02
1
2023 - 04 - 28
1
2023 - 04 - 20
3
2023 - 04 - 17
1
2023 - 04 - 04
1
2023 - 03 - 31
1
2023 - 03 - 29
1
2023 - 03 - 28
2
2023 - 03 - 21
1
2023 - 03 - 08
1
2023 - 03 - 07
1
2023 - 02 - 28
2
2023 - 02 - 17
1
2023 - 02 - 15
1
2023 - 01 - 27
1
2023 - 01 - 26
1
2023 - 01 - 11
1
2023 - 01 - 06
1
2023 - 01 - 05
1
2022 - 12 - 15
1
2022 - 12 - 09
1
2022 - 12 - 05
1
2022 - 11 - 28
1
2022 - 11 - 15
1
2022 - 11 - 14
1
2022 - 11 - 09
1
2022 - 11 - 07
1
2022 - 10 - 31
1
2022 - 10 - 17
1
2022 - 10 - 10
2
2022 - 09 - 08
1
2022 - 09 - 06
1
2022 - 09 - 05
1
2022 - 08 - 31
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 12
1
2022 - 08 - 10
1
2022 - 08 - 08
2
2022 - 07 - 28
1
2022 - 02 - 25
1
2022 - 02 - 01
1
2022 - 01 - 12
1
2021 - 12 - 22
1
2021 - 12 - 14
1
2021 - 11 - 05
1
Crawled Time
00:00
103
00:20
20
01:00
84
02:00
48
03:00
34
04:00
27
04:20
14
05:00
65
06:00
103
07:00
120
08:00
91
08:20
4
09:00
92
10:00
88
11:00
218
12:00
257
12:15
9
12:20
70
12:30
41
13:00
218
13:15
8
13:20
59
13:30
56
14:00
185
14:15
12
14:20
48
14:30
56
15:00
153
15:15
6
15:20
50
15:30
66
16:00
182
16:20
26
17:00
189
18:00
148
19:00
120
20:00
118
20:20
18
21:00
159
22:00
130
23:00
102
Source
spacfeed.com
6
www.biospace.com
5
www.globenewswire.com
6
www.modeln.com
1
www.prnewswire.com
66
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
SNYNF
crawled time :
01:00
save search
Global IgG Mediated Autoimmune Diseases Biologic Drugs Research Report 2023-2029: Shift Towards Personalized Medicine and Targeted Therapies & Adoption of Biosimilars and Biobetters
Published:
2024-03-13
(Crawled : 01:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
-4.76%
|
O:
-0.23%
H:
0.0%
C:
0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-5.42%
|
O:
-0.07%
H:
0.09%
C:
-0.7%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-8.36%
|
O:
0.66%
H:
0.0%
C:
0.0%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
-3.79%
|
O:
0.27%
H:
0.5%
C:
0.11%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-8.28%
|
O:
0.59%
H:
0.01%
C:
-1.45%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.22%
|
O:
-0.04%
H:
0.0%
C:
0.0%
report
research
global
Janus Kinase (JAK) Inhibitors Global Market Report 2024, Featuring Key Players Pfizer, Merck, AbbVie, Novartis, Sanofi, Bristol Myers Squibb, GSK, Takeda, Eli Lilly and Gilead Sciences
Published:
2024-03-05
(Crawled : 01:00)
- prnewswire.com
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-7.46%
|
O:
0.32%
H:
0.22%
C:
-0.2%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-6.86%
|
O:
-0.24%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.49%
|
O:
1.17%
H:
0.0%
C:
0.0%
report
sciences
global
key
market
Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Analysis Report 2024: A $133.5 Billion in 2030 Featuring Eli Lilly and Co, Pfizer, Sanofi, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk
Published:
2024-02-27
(Crawled : 01:00)
- prnewswire.com
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
|
4.78%
|
O:
-1.72%
H:
2.54%
C:
2.54%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
-5.91%
|
O:
-2.2%
H:
2.39%
C:
1.34%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-5.14%
|
O:
-0.94%
H:
0.0%
C:
0.0%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
|
3.97%
|
O:
0.01%
H:
0.79%
C:
0.6%
report
agonist
global
market
North America and Europe Bus ADAS Market Analysis and Growth Opportunities, 2022-2024 and Forecasts to 2030: Coach Buses to Incorporate Significant ADAS Features while Transit Buses Move Toward Autonomy
Published:
2024-02-27
(Crawled : 01:00)
- prnewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-5.14%
|
O:
-0.94%
H:
0.0%
C:
0.0%
america
europe
bus
growth
coach
market
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published:
2024-02-22
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-5.87%
|
O:
0.14%
H:
0.0%
C:
-0.0%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-3.13%
|
O:
0.26%
H:
1.36%
C:
1.36%
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
|
7.24%
|
O:
-0.85%
H:
1.12%
C:
0.43%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
-8.14%
|
O:
0.92%
H:
0.0%
C:
0.0%
UCBJY
|
$63.676
-4.38%
7.2K
|
Manufacturing
|
26.78%
|
O:
1.46%
H:
0.44%
C:
0.44%
ALPMY
|
$9.47
-1.11%
520K
|
Manufacturing
|
-14.57%
|
O:
-0.27%
H:
0.0%
C:
-1.17%
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
|
-10.18%
|
O:
-0.2%
H:
0.14%
C:
-0.48%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-8.0%
|
O:
-0.06%
H:
0.46%
C:
0.29%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
|
-5.22%
|
O:
-0.69%
H:
1.42%
C:
1.22%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
-2.63%
|
O:
2.37%
H:
1.51%
C:
0.79%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
|
-3.89%
|
O:
-0.65%
H:
1.63%
C:
1.48%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-5.63%
|
O:
-0.88%
H:
1.46%
C:
1.13%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.76%
|
O:
1.67%
H:
0.0%
C:
0.0%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
|
5.32%
|
O:
-2.81%
H:
2.08%
C:
1.38%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
-5.13%
|
O:
-0.35%
H:
1.15%
C:
0.96%
lung
reach
cancer
cell
diagnostics
therapy
market
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published:
2024-02-20
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.38%
|
O:
2.72%
H:
0.0%
C:
-0.8%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
0.15%
|
O:
2.53%
H:
0.0%
C:
0.0%
ibi311
disease
thyroid
eye
trial
Global Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report 2023-2030
Published:
2024-02-13
(Crawled : 01:00)
- prnewswire.com
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-5.55%
|
O:
0.7%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
0.22%
|
O:
-0.06%
H:
0.0%
C:
0.0%
report
global
trends
therapeutics
market
Global Biopharmaceutical Fermentation Market Analysis Report 2023-2028: Expanding Biosimilars Market, Continuous Fermentation Processes, and Growing Pipeline of Biopharmaceuticals Bolster Growth
Published:
2023-12-15
(Crawled : 01:00)
- prnewswire.com
LZAGF
|
$563.5
-19.1%
6
|
Health Technology
|
43.64%
|
O:
4.1%
H:
0.31%
C:
-1.9%
LZAGY
|
$55.65
0.02%
32K
|
Professional, Scientific, and T...
|
44.9%
|
O:
3.28%
H:
0.46%
C:
-0.61%
TMO
|
News
|
$544.78
0.6%
0.0%
1.7M
|
Health Technology
|
3.38%
|
O:
-1.41%
H:
0.0%
C:
0.0%
DHR
|
$235.51
-0.36%
0.0%
2.3M
|
Health Technology
|
2.73%
|
O:
0.24%
H:
0.05%
C:
-1.11%
BDX
|
$234.12
0.42%
0.0%
1.3M
|
Health Technology
|
-1.84%
|
O:
-1.8%
H:
1.46%
C:
1.19%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.14%
|
O:
-0.93%
H:
0.0%
C:
0.0%
report
pipeline
global
growing
growth
market
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
Published:
2023-12-11
(Crawled : 01:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-0.54%
|
O:
0.5%
H:
1.67%
C:
0.1%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
0.19%
|
O:
2.15%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
6.75%
|
O:
-0.2%
H:
1.35%
C:
1.19%
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Published:
2023-12-11
(Crawled : 01:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-0.54%
|
O:
0.5%
H:
1.67%
C:
0.1%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
0.19%
|
O:
2.15%
H:
0.0%
C:
0.0%
sarclisa
disease
plus
Global Bioreactors Market Forecast Report 2023-2033: Influence of Single-use Technologies on Market Direction
Published:
2023-12-08
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
2.34%
|
O:
2.06%
H:
0.82%
C:
0.82%
TMO
|
News
|
$544.78
0.6%
0.0%
1.7M
|
Health Technology
|
10.19%
|
O:
-0.22%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-5.17%
|
O:
-0.18%
H:
0.0%
C:
0.0%
DHR
|
$235.51
-0.36%
0.0%
2.3M
|
Health Technology
|
7.58%
|
O:
0.04%
H:
0.46%
C:
-0.69%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
1.27%
|
O:
1.07%
H:
0.0%
C:
0.0%
report
global
market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published:
2023-12-07
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.64%
|
O:
-1.66%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
0.06%
|
O:
-1.19%
H:
0.0%
C:
0.0%
positive
ongoing
collaboration
study
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published:
2023-12-06
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-1.66%
|
O:
-2.77%
H:
0.49%
C:
0.49%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
24.61%
|
O:
0.99%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.54%
|
O:
-0.6%
H:
0.0%
C:
0.0%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
|
-4.51%
|
O:
-0.2%
H:
1.7%
C:
1.3%
rient-16
treatment
results
study
Drugs For Benign Prostatic Hypertrophy Market Report 2024 - Market to Reach $5.45 billion in 2028 - Opportunities in Minimally Invasive Treatments, Personalized Medicine and Combination Therapies
Published:
2023-12-06
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-1.66%
|
O:
-2.77%
H:
0.49%
C:
0.49%
ABT
|
News
|
$107.28
1.91%
0.18%
10M
|
Health Technology
|
2.0%
|
O:
-0.59%
H:
0.0%
C:
0.0%
VERU
|
$1.305
-8.1%
-8.81%
2.6M
|
Health Technology
|
32.32%
|
O:
-1.01%
H:
14.29%
C:
13.27%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.54%
|
O:
-0.6%
H:
0.0%
C:
0.0%
report
reach
market
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published:
2023-11-24
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-0.32%
|
O:
0.69%
H:
1.66%
C:
1.66%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.28%
|
O:
1.46%
H:
0.0%
C:
0.0%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
|
-1.97%
|
O:
0.34%
H:
0.37%
C:
0.3%
ibi351
drug
granted
review
designation
medical
application
china
Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market
Published:
2023-11-01
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
12.22%
|
O:
-1.62%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
3.73%
|
O:
0.94%
H:
2.55%
C:
2.55%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
2.99%
|
O:
2.52%
H:
0.04%
C:
0.04%
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
|
27.07%
|
O:
0.87%
H:
0.73%
C:
0.28%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
0.83%
|
O:
0.16%
H:
0.7%
C:
0.57%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
|
11.34%
|
O:
-4.06%
H:
1.9%
C:
0.96%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
27.81%
|
O:
-2.76%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
1.62%
|
O:
0.18%
H:
0.0%
C:
0.0%
expected
reach
global
dna
medical
technology
market
Technological Advancements and Research Efforts Propel Neuromuscular Disease Therapeutics Market Growth
Published:
2023-10-27
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-11.93%
|
O:
-18.18%
H:
0.0%
C:
0.0%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
-1.63%
|
O:
-3.68%
H:
0.0%
C:
0.0%
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
|
25.14%
|
O:
0.0%
H:
0.17%
C:
-2.45%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
0.06%
|
O:
-0.23%
H:
0.08%
C:
-1.92%
BHC
|
$8.69
1.05%
0.0%
2.9M
|
Health Technology
|
29.12%
|
O:
-0.59%
H:
0.15%
C:
-1.79%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-12.87%
|
O:
-15.73%
H:
0.0%
C:
0.0%
BCLI
A
|
$0.5384
4.69%
4.48%
1M
|
Health Technology
|
229.19%
|
O:
3.73%
H:
1.8%
C:
-4.19%
BIIB
|
$194.39
2.03%
1.99%
1.6M
|
Health Technology
|
-19.37%
|
O:
-0.45%
H:
0.12%
C:
-2.28%
propel
disease
research
therapeutics
growth
market
Pharmaceutical Suppositories Market to Reach $2.8 Billion, Globally, by 2032 at 5.7% CAGR: Allied Market Research
Published:
2023-10-24
(Crawled : 01:00)
- prnewswire.com
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
|
26.12%
|
O:
0.45%
H:
2.46%
C:
1.67%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-0.35%
|
O:
-0.17%
H:
1.02%
C:
0.4%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-10.94%
|
O:
0.77%
H:
0.0%
C:
0.0%
reach
research
market
Global Alport Syndrome Treatment Market Set to Surge, Projected to Reach USD 19.00 Million by 2032
Published:
2023-08-31
(Crawled : 01:00)
- prnewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-14.81%
|
O:
-0.66%
H:
0.0%
C:
0.0%
reach
treatment
global
set
market
Empowering Healthcare: Global Vaccine Management System Market to Reach $441.17 million by 2028
Published:
2023-08-30
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
11.79%
|
O:
-1.57%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
|
-2.08%
|
O:
0.56%
H:
0.0%
C:
-2.26%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-8.64%
|
O:
-0.25%
H:
0.47%
C:
-1.08%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-10.18%
|
O:
0.56%
H:
0.0%
C:
0.0%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
|
11.94%
|
O:
0.54%
H:
0.27%
C:
-0.59%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-14.25%
|
O:
0.66%
H:
0.0%
C:
0.0%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
|
-0.85%
|
O:
0.46%
H:
0.17%
C:
-0.86%
management
vaccine
reach
global
system
market
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
JOE
4
|
$54.88
1.22%
0.22%
210K
|
Finance
JBI
4
|
$15.14
1.34%
0.0%
2.9M
|
Your saved searches
Save your searches and get alerts when important news are released.